Determination of the Plasma Levels of Growth Arrest Specific 6 in Colon Cancer Patients-Reference-Cited by-同舟云学术

Determination of the Plasma Levels of Growth Arrest Specific 6 in Colon Cancer Patients

Published:2023-06-15 Issue:2 Volume:13 Page:400-403
ISSN:2459-1459
Container-title:Clinical and Experimental Health Sciences
language:
Short-container-title:

Author:

TEZCAN Songul¹^ORCID,İZZETTİN Fikret²^ORCID,BİNGÖL ÖZAKPINAR Özlem¹^ORCID,ATTAALLAH Vafi³^ORCID,YUMUK Perran⁴^ORCID,URAS Fikriye¹^ORCID

Affiliation:

1. Marmara University

2. Bezmialem Vakif University

3. Anadolu Medical Center

4. KOC UNIVERSITY

Abstract

Objective: Growth arrest-specific 6 (GAS 6) has a role in cell proliferation and was detected in different cancer types. The aim of this study was to evaluate the plasma GAS 6 levels in colon cancer patients. Methods: This was a prospective study and conducted in a research and training hospital in Turkey. Thirty-three healthy volunteers were enrolled in the control group, thirty-three colon cancer patients who were diagnosed with colon cancer for the first time. Sociodemographic characteristics of participants were recorded. Blood samples of the control group were taken once a time. Patients’ blood samples were taken before and one month after surgery. Results: There were no statistically significant differences between the sociodemographic characteristics of the two groups. The mean plasma GAS 6 levels in control were significantly higher than that of colon cancer patients (p

Publisher

Marmara University

Subject

General Materials Science

Reference25 articles.

1. Hafizi S, Dahlbäck B. GAS 6 and protein S: Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS Journal 2006;273:5231–5244. DOI: 10.1111/j.1742-4658.2006.05529.x.

2. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (GAS 6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993;13(8):4976-4985. DOI: 10.1128/mcb.13.8.4976-4985.1993.

3. Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer 2019;18(1):94. DOI: 10.1186/s12943-019-1022-2.

4. Ni BK, Cai JY, Wang XB, Lin Q, Zhang XN, Wu JH. Utility of serum growth arrest-specific protein 6 as a biomarker of severity and prognosis after severe traumatic brain injury: A prospective observational study. Neuropsychiatr Dis Treat. 2022;18:1441-1453. DOI: 10.2147/NDT.S372904.

5. Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018; 6;19(11):3491. DOI: 10.3390/ijms19113491.